NCT03422393 2024-07-05
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
University of California, San Diego
Phase 1 Active not recruiting
Clinical Trials
5 trialsNCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03150602 2017-05-12
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Unknown
NCT00530140 2011-10-06
FLIDVAX2006
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown